Abstract:Choroidal neovascularization (CNV) is the common pathological basis of irreversible visual impairment encountered in a variety of chorioretinal diseases; the pathogenesis of its development is complicated and still imperfectly understood. Recent studies indicated that delta-like ligand 4 (Dll4), one of the Notch family ligands might participate in the HIF-1 alpha-VEGF pathway to regulate CNV angiogenesis. But little is known about the influence and potential mechanism of Dll4/Notch signals on CNV angiogenesis. Real-time RT-PCR, Western blotting were used to analyze the expression alteration of Dll4, VEGF and HIF-1 alpha in hypoxic RF/6A cells. Immunofluorescence staining, a laser-induced rat CNV model and intravitreal injection techniques were used to confirm the relationships among these molecules in vitro and in vivo. RPE-RF/6A cell co-culture systems were used to investigate the effects of Dll4/Notch signals on CNV angiogenesis. We found that the Dll4 was involved in hypoxia signaling in CNV angiogenesis. Results from the co-culture system showed that the enhancement of Dll4 expression in RF/6A cells led to the significantly faster proliferation and stronger tube forming ability, but inhibited cells migration and invasion across a monolayer of RPE cells in hypoxic environment, while siRNA-mediated Dll4 silencing caused the opposite effects. Pharmacological disruption of Notch signaling using gamma-secretase inhibitor (GSI) produced similar, but not identical effects, to that caused by the Dll4 siRNA. In addition, the expression of several key molecules involved in the angiogenesis of CNV was altered in RF/6A cells showing constitutively active Dll4 expression. These results suggest that Dll4 play an important role in CNV angiogenesis, which appears to be regulated by HIF-1 alpha and VEGF during the progression of CNV under hypoxic conditions. Targeting Dll4/Notch signaling may facilitate further understanding of the mechanisms that underlie CNV angiogenesis.

Correlation of Delta-like Ligand 4 (DLL4) with VEGF and HIF-1α Expression in Human Glioma.

Delta-like ligand 4 correlates with endothelial proliferation and vessel maturation in human malignant glioma.

Delta-Like Ligand 4 Expression in Human Gliomas and Its Relationship with Angiogenesis

Influence of Up-Regulation of Notch Ligand DLL4 on Biological Behaviors of Human Gastric Cancer Cells.

CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.

[Expression of DLL4 and VEGF in Lung Adenocarcinoma and Their Relationship with Angiogenesis in Tumor.].

Expression and significance of vascuIar endothelial growth factor and Ⅷ-R Ag in human brain glioma

Expression of Delta Like Ligand 4 in Pancreatic Cancer and Its Relationship with Angiogenesis

Expression and significance of vascuIar endothelial growth factor and VIII-R Ag in human brain glioma

High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis after Curative Resection for Pancreatic Cancer

Elevated DLL4 Expression is Correlated with VEGF and Predicts Poor Prognosis of Nasopharyngeal Carcinoma

Expression and Role of Delta-like 4 in Pancreatic Cancer

Overexpressions of DLL4 and CD105 Are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma

Delta-like ligand 4 and tumor treatment

Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer.

Delta-like ligand 4 level in colorectal cancer is associated with tumor aggressiveness and clinical outcome

Correlation Between Txpression Changes of Vascular Endothelial Growth Factor Gene in Human Gliomas and Hedgehog/Gli Signaling Pathway

Blocking of DLL4/Notch Signaling Deregulates Tumor Angiogenesis

The Significance of the Expression of DLL4 and VEGF in Patients with Bladder Transitional Cell Carcinoma

Influence Of Dll4 Via Hif-1 Alpha-Vegf Signaling On The Angiogenesis Of Choroidal Neovascularization Under Hypoxic Conditions

Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer.